Duvakitug Antibody Shows Positive Results in IBD Clinical Trials

Detailed findings from the phase 2b RELIEVE UCCD trial indicate that the investigational anti-TL1A monoclonal antibody, duvakitug, significantly improved clinical remission rates in adults with moderate to severe ulcerative colitis. The drug also demonstrated enhanced endoscopic response rates in patients with Crohn's disease. High-dose duvakitug achieved substantial remission and response rates compared to placebo, offering hope for new treatments for these inflammatory bowel diseases.